Quantitative assessment of 18F-FDG PET in patients with Hodgkin lymphoma
- 1 March 2019
- journal article
- research article
- Published by Wolters Kluwer Health in Nuclear Medicine Communications
- Vol. 40 (3) , 249-257
Abstract
The reliability of visual and quantitative response assessment may be impaired owing to inconsistent scanning protocols and image reconstruction methods of 2-deoxy-2-[18F]fluoro-D-glucose (18F-FDG) PET. Hence, this study investigates the effect of contrast-enhanced computed tomography (CT) attenuation correction in patients with Hodgkin lymphoma. In 10 consecutive patients undergoing either staging or response assessment, 18F-FDG PET images were attenuation-corrected once on the basis of unenhanced CT and additionally using contrast-enhanced CT. Reconstruction was performed in both cases with ordered subset expectation maximization (OSEM) and ultra-high definition (UHD) algorithm. While maximum and peak standardized uptake value (SUV) were obtained from tumour tissue (lesionSUVmax and lesionSUVpeak), maximum and mean SUVs were determined within the background regions liver (liverSUVmax and liverSUVmean) and mediastinal blood pool (mbpSUVmax and mbpSUVmean). After switching to contrast-enhanced CT attenuation correction, lesionSUVmax and lesionSUVpeak increased on average by 2.55±3.24 (P=0.018) and 3.64±3.22% (P=0.008), respectively, with OSEM and by 4.59±5.49 (P=0.005) and 3.84±5.65% (P=0.005), respectively, with UHD reconstruction. LiverSUVmax and liverSUVmean showed a mean rise of 7.15±4.27 (P=0.005) and 6.97±2.18% (P=0.005), respectively, in the OSEM data sets and of 7.24±6.59 (P=0.017) and 6.29±2.83% (P=0.005), respectively, in the UHD images. The average increases of mbpSUVmax and mbpSUVmean were 10.82±4.89 (P=0.005) and 12.40±3.73% (P=0.005), respectively, after OSEM, compared with 13.11±14.93 (P=0.005) and 11.50±12.19% (P=0.005), respectively, after UHD reconstruction. As the use of CT contrast fluids results in a stronger SUV increase within the liver and mediastinal blood pool than within lymphoma tissue, this may have clinical consequences regarding visual and quantitative response assessment. Ideally, CT scans for PET attenuation correction should therefore be performed in the absence of a contrast agent.Keywords
This publication has 23 references indexed in Scilit:
- PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study GroupThe Lancet, 2017
- Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphomaBlood, 2017
- Early Positron Emission Tomography Response–Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 TrialJournal of Clinical Oncology, 2017
- Results of a Trial of PET-Directed Therapy for Early-Stage Hodgkin’s LymphomaNew England Journal of Medicine, 2015
- qPET – a quantitative extension of the Deauville scale to assess response in interim FDG-PET scans in lymphomaEuropean Journal of Nuclear Medicine and Molecular Imaging, 2014
- Interim 18F-FDG PET SUVmax Reduction Is Superior to Visual Analysis in Predicting Outcome Early in Hodgkin Lymphoma PatientsJournal of Nuclear Medicine, 2014
- An international confirmatory study of the prognostic value of early PET/CT in diffuse large B-cell lymphoma: comparison between Deauville criteria and ΔSUVmaxEuropean Journal of Nuclear Medicine and Molecular Imaging, 2013
- International Validation Study for Interim PET in ABVD-Treated, Advanced-Stage Hodgkin Lymphoma: Interpretation Criteria and Concordance Rate Among ReviewersJournal of Nuclear Medicine, 2013
- High SUV uptake on FDG–PET/CT predicts for an aggressive B-cell lymphoma in a prospective study of primary FDG–PET/CT staging in lymphomaAnnals of Oncology, 2009
- Report on the First International Workshop on interim-PET scan in lymphomaLeukemia & Lymphoma, 2009